Be A Freedom Fighter · Bill Library
HR 10649 — Safe Disposal of Opioids Act of 2026
Freedom score: -2 (scale −10 to +10)
- Individual rights: 0
- Property rights: 0
- Economic freedom: -1
- Privacy & due process: 0
- Government power: -1
Sponsor: · Latest action: ()
Full text on GovInfo (introduced version) · Congress.gov · ← Bill Library index
Findings — 5 highlighted provisions
Each item below is one provision documented in the findings file. The same provision is highlighted in the full text underneath, with its section citation and criterion. Everything else on this page is plain, unreviewed bill text.
- Sec. 2, new 21 U.S.C. §822a(c)(2)(A)–(B) · Individual Rights — HHS must arrange point-of-purchase discounting so qualifying cancer-pain patients, hospice patients and listed representatives do not bear the new opioid fee; this is a financial safeguard, not a newly enforceable general treatment right See in text ↓
- Sec. 2, new §822a(c)(3)(A)–(B) · Economic Freedom — A mandatory fee of one cent per 100 milligrams applies to sales of active opioids by manufacturers, producers and importers. Scope excludes prescribed drugs used exclusively to treat opioid addiction; where mixed ingredients exist, only opioid fraction is included. No new criminal offense appears in this text See in text ↓
- Sec. 2, new §822a(c)(1)(A)–(B) · Economic Freedom — Attorney General shall award grants to covered entities for unwanted-prescription disposal sites. Annual awards to law-enforcement agencies or prescription manufacturers/distributors/reverse distributors may not exceed 10% of total; eligible nonlisted recipients are defined by underlying Act See in text ↓
- Sec. 2, new §822a(c)(4) · Economic Freedom — FY 2027 onward appropriations are authorized, each year capped at the aggregate opioid fees collected; the authorization does not itself appropriate collections See in text ↓
- Sec. 2, new §822a(c)(1)–(4) · Government Power — New federal fee collection, mandatory grant awards, and HHS discount administration. Fee enforcement depends on existing tax/fee statutes and regulations, not an express new penalty in this bill See in text ↓
Full text (introduced version)
6 of 7 text blocks highlighted. Source: GovInfo, fetched cached.
SECTION 1. SHORT TITLE.
SEC. 2. GRANTS FOR DISPOSAL SITES FOR UNWANTED PRESCRIPTION MEDICATIONS.
Sec. 2, new 21 U.S.C. §822a(c)(2)(A)–(B) · Individual Rights — HHS must arrange point-of-purchase discounting so qualifying cancer-pain patients, hospice patients and listed representatives do not bear the new opioid fee; this is a financial safeguard, not a newly enforceable general treatment right
Sec. 2, new §822a(c)(3)(A)–(B) · Economic Freedom — A mandatory fee of one cent per 100 milligrams applies to sales of active opioids by manufacturers, producers and importers. Scope excludes prescribed drugs used exclusively to treat opioid addiction; where mixed ingredients exist, only opioid fraction is included. No new criminal offense appears in this text
Sec. 2, new §822a(c)(1)(A)–(B) · Economic Freedom — Attorney General shall award grants to covered entities for unwanted-prescription disposal sites. Annual awards to law-enforcement agencies or prescription manufacturers/distributors/reverse distributors may not exceed 10% of total; eligible nonlisted recipients are defined by underlying Act
Sec. 2, new §822a(c)(4) · Economic Freedom — FY 2027 onward appropriations are authorized, each year capped at the aggregate opioid fees collected; the authorization does not itself appropriate collections
Sec. 2, new §822a(c)(1)–(4) · Government Power — New federal fee collection, mandatory grant awards, and HHS discount administration. Fee enforcement depends on existing tax/fee statutes and regulations, not an express new penalty in this bill
Sec. 2, new 21 U.S.C. §822a(c)(2)(A)–(B) · Individual Rights — HHS must arrange point-of-purchase discounting so qualifying cancer-pain patients, hospice patients and listed representatives do not bear the new opioid fee; this is a financial safeguard, not a newly enforceable general treatment right
Sec. 2, new §822a(c)(3)(A)–(B) · Economic Freedom — A mandatory fee of one cent per 100 milligrams applies to sales of active opioids by manufacturers, producers and importers. Scope excludes prescribed drugs used exclusively to treat opioid addiction; where mixed ingredients exist, only opioid fraction is included. No new criminal offense appears in this text
Sec. 2, new §822a(c)(1)(A)–(B) · Economic Freedom — Attorney General shall award grants to covered entities for unwanted-prescription disposal sites. Annual awards to law-enforcement agencies or prescription manufacturers/distributors/reverse distributors may not exceed 10% of total; eligible nonlisted recipients are defined by underlying Act
Sec. 2, new §822a(c)(4) · Economic Freedom — FY 2027 onward appropriations are authorized, each year capped at the aggregate opioid fees collected; the authorization does not itself appropriate collections
Sec. 2, new §822a(c)(1)–(4) · Government Power — New federal fee collection, mandatory grant awards, and HHS discount administration. Fee enforcement depends on existing tax/fee statutes and regulations, not an express new penalty in this bill
Sec. 2, new 21 U.S.C. §822a(c)(2)(A)–(B) · Individual Rights — HHS must arrange point-of-purchase discounting so qualifying cancer-pain patients, hospice patients and listed representatives do not bear the new opioid fee; this is a financial safeguard, not a newly enforceable general treatment right
Sec. 2, new §822a(c)(3)(A)–(B) · Economic Freedom — A mandatory fee of one cent per 100 milligrams applies to sales of active opioids by manufacturers, producers and importers. Scope excludes prescribed drugs used exclusively to treat opioid addiction; where mixed ingredients exist, only opioid fraction is included. No new criminal offense appears in this text
Sec. 2, new §822a(c)(1)(A)–(B) · Economic Freedom — Attorney General shall award grants to covered entities for unwanted-prescription disposal sites. Annual awards to law-enforcement agencies or prescription manufacturers/distributors/reverse distributors may not exceed 10% of total; eligible nonlisted recipients are defined by underlying Act
Sec. 2, new §822a(c)(4) · Economic Freedom — FY 2027 onward appropriations are authorized, each year capped at the aggregate opioid fees collected; the authorization does not itself appropriate collections
Sec. 2, new §822a(c)(1)–(4) · Government Power — New federal fee collection, mandatory grant awards, and HHS discount administration. Fee enforcement depends on existing tax/fee statutes and regulations, not an express new penalty in this bill
Sec. 2, new 21 U.S.C. §822a(c)(2)(A)–(B) · Individual Rights — HHS must arrange point-of-purchase discounting so qualifying cancer-pain patients, hospice patients and listed representatives do not bear the new opioid fee; this is a financial safeguard, not a newly enforceable general treatment right
Sec. 2, new §822a(c)(3)(A)–(B) · Economic Freedom — A mandatory fee of one cent per 100 milligrams applies to sales of active opioids by manufacturers, producers and importers. Scope excludes prescribed drugs used exclusively to treat opioid addiction; where mixed ingredients exist, only opioid fraction is included. No new criminal offense appears in this text
Sec. 2, new §822a(c)(1)(A)–(B) · Economic Freedom — Attorney General shall award grants to covered entities for unwanted-prescription disposal sites. Annual awards to law-enforcement agencies or prescription manufacturers/distributors/reverse distributors may not exceed 10% of total; eligible nonlisted recipients are defined by underlying Act
Sec. 2, new §822a(c)(4) · Economic Freedom — FY 2027 onward appropriations are authorized, each year capped at the aggregate opioid fees collected; the authorization does not itself appropriate collections
Sec. 2, new §822a(c)(1)–(4) · Government Power — New federal fee collection, mandatory grant awards, and HHS discount administration. Fee enforcement depends on existing tax/fee statutes and regulations, not an express new penalty in this bill
Sec. 2, new 21 U.S.C. §822a(c)(2)(A)–(B) · Individual Rights — HHS must arrange point-of-purchase discounting so qualifying cancer-pain patients, hospice patients and listed representatives do not bear the new opioid fee; this is a financial safeguard, not a newly enforceable general treatment right
Sec. 2, new §822a(c)(3)(A)–(B) · Economic Freedom — A mandatory fee of one cent per 100 milligrams applies to sales of active opioids by manufacturers, producers and importers. Scope excludes prescribed drugs used exclusively to treat opioid addiction; where mixed ingredients exist, only opioid fraction is included. No new criminal offense appears in this text
Sec. 2, new §822a(c)(1)(A)–(B) · Economic Freedom — Attorney General shall award grants to covered entities for unwanted-prescription disposal sites. Annual awards to law-enforcement agencies or prescription manufacturers/distributors/reverse distributors may not exceed 10% of total; eligible nonlisted recipients are defined by underlying Act
Sec. 2, new §822a(c)(4) · Economic Freedom — FY 2027 onward appropriations are authorized, each year capped at the aggregate opioid fees collected; the authorization does not itself appropriate collections
Sec. 2, new §822a(c)(1)–(4) · Government Power — New federal fee collection, mandatory grant awards, and HHS discount administration. Fee enforcement depends on existing tax/fee statutes and regulations, not an express new penalty in this bill
Sec. 2, new 21 U.S.C. §822a(c)(2)(A)–(B) · Individual Rights — HHS must arrange point-of-purchase discounting so qualifying cancer-pain patients, hospice patients and listed representatives do not bear the new opioid fee; this is a financial safeguard, not a newly enforceable general treatment right
Sec. 2, new §822a(c)(3)(A)–(B) · Economic Freedom — A mandatory fee of one cent per 100 milligrams applies to sales of active opioids by manufacturers, producers and importers. Scope excludes prescribed drugs used exclusively to treat opioid addiction; where mixed ingredients exist, only opioid fraction is included. No new criminal offense appears in this text
Sec. 2, new §822a(c)(1)(A)–(B) · Economic Freedom — Attorney General shall award grants to covered entities for unwanted-prescription disposal sites. Annual awards to law-enforcement agencies or prescription manufacturers/distributors/reverse distributors may not exceed 10% of total; eligible nonlisted recipients are defined by underlying Act
Sec. 2, new §822a(c)(4) · Economic Freedom — FY 2027 onward appropriations are authorized, each year capped at the aggregate opioid fees collected; the authorization does not itself appropriate collections
Sec. 2, new §822a(c)(1)–(4) · Government Power — New federal fee collection, mandatory grant awards, and HHS discount administration. Fee enforcement depends on existing tax/fee statutes and regulations, not an express new penalty in this bill
Findings source: bill-scores-v2-batch55-findings-2026-11-15.md. Highlights come only from that file; no finding, score, or provision was invented for this page.
What you can do
Contact your U.S. Representative and Senators about this bill.
Find your Representative Contact your Senators
Spot an error on this page? Report it.